Marla Kessler Net Worth

The estimated Net Worth of Marla L Kessler is at least $949 Thousand dollars as of 14 December 2023. Ms. Kessler owns over 9,926 units of Ironwood Pharmaceuticals Inc stock worth over $420,088 and over the last 6 years she sold IRWD stock worth over $199,728. In addition, she makes $329,431 as Independent Director at Ironwood Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Kessler IRWD stock SEC Form 4 insiders trading

Marla has made over 2 trades of the Ironwood Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently she sold 9,926 units of IRWD stock worth $111,072 on 14 December 2023.

The largest trade she's ever made was selling 9,926 units of Ironwood Pharmaceuticals Inc stock on 14 December 2023 worth over $111,072. On average, Marla trades about 1,948 units every 61 days since 2019. As of 14 December 2023 she still owns at least 96,572 units of Ironwood Pharmaceuticals Inc stock.

You can see the complete history of Ms. Kessler stock trades at the bottom of the page.

Marla Kessler biography

Marla L. Kessler is Independent Director of the Company. She joined our board of directors in April 2019. Ms. Kessler has been the senior vice president of IQVIA (formerly IMS Health and Quintiles) since 2016, leading strategy, marketing and communications. Previously, Ms. Kessler served in various roles of increasing responsibility at IMS Health including vice president for real world evidence marketing, European lead for IMS Consulting Group, location manager for the London IMS Consulting Group and senior principal. Before joining IQVIA, Ms. Kessler led several marketing, public affairs and consulting roles at Pfizer Inc. and McKinsey & Company. Ms. Kessler has a B.S. in economics from Arizona State University and an MBA from the Fuqua School of Business at Duke University. Ms. Kessler provides an important commercial perspective to our board of directors given her expertise in strategic marketing, evidence-based research and customer experience in the life science industry.

What is the salary of Marla Kessler?

As the Independent Director of Ironwood Pharmaceuticals Inc, the total compensation of Marla Kessler at Ironwood Pharmaceuticals Inc is $329,431. There are 9 executives at Ironwood Pharmaceuticals Inc getting paid more, with Mark Mallon having the highest compensation of $10,068,800.

How old is Marla Kessler?

Marla Kessler is 50, she's been the Independent Director of Ironwood Pharmaceuticals Inc since 2019. There are 13 older and 5 younger executives at Ironwood Pharmaceuticals Inc. The oldest executive at Ironwood Pharmaceuticals Inc is Edward Owens, 73, who is the Independent Director.

What's Marla Kessler's mailing address?

Marla's mailing address filed with the SEC is C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON, MA, 02110.

Insiders trading at Ironwood Pharmaceuticals Inc

Over the last 15 years, insiders at Ironwood Pharmaceuticals Inc have traded over $83,928,361 worth of Ironwood Pharmaceuticals Inc stock and bought 2,478,676 units worth $24,100,589 . The most active insiders traders include Llc Fmr, Bryan E Roberts, and Alexander J Denner. On average, Ironwood Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of $239,611. The most recent stock trade was executed by Minardo John on 12 August 2024, trading 9,910 units of IRWD stock currently worth $42,316.

What does Ironwood Pharmaceuticals Inc do?

ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b

Complete history of Ms. Kessler stock trades at Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc executives and stock owners

Ironwood Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Mark Mallon,
  Chief Executive Officer, Director
• Thomas McCourt,
  President
• Mark Currie,
  Director
• Gina Consylman,
  Chief Financial Officer, Senior Vice President
• Thomas A. McCourt,
  CEO & Director
• Jason Rickard,
  COO & Sr. VP of Operations
• Dr. Michael Shetzline M.D., Ph.D.,
  Chief Medical Officer, Sr. VP and Head of R&D
• Catherine Moukheibir,
  Independent Director
• Jon Duane,
  Independent Director
• Marla Kessler,
  Independent Director
• Julie McHugh,
  Independent Chairman of the Board
• Andrew Dreyfus,
  Independent Director
• Edward Owens,
  Independent Director
• Lawrence Olanoff,
  Independent Director
• Julie H. McHugh,
  Exec. Chairman
• Alexander Denner,
  Director
• Meredith Kaya,
  Vice President - Investor Relations and Corporate Communications
• Michael Shetzline,
  Chief Medical Officer, Senior Vice President and Head of Drug Development
• Conor Kilroy,
  Senior Vice President, General Counsel
• Jason Rickard,
  Chief Operating Officer, Senior Vice President
• John Minardo,
  Sr. VP & Chief Legal Officer
• Marcel Moulaison,
  VP of Technical Operations
• Ronald Silver,
  Corp. Controller & Principal Accounting Officer
• Sravan Kumar Emany,
  Sr. VP & CFO
• G. Todd Milne,
  Co-Founder and VP of sGC R&D
• Brian M. Cali,
  Co-Founder and Sr. VP of R&D Strategy & External Innovation
• Terrance Mcguire,
  Director
• Douglas E Williams,
  Director
• Amy W Schulman,
  Director
• Marsha Fanucci,
  Director
• Christopher T Phd Walsh,
  Director
• Peter M Hecht,
  Chief Executive Officer
• Thomas Graney,
  Chief Financial Officer
• William Huyett,
  Chief Operating Officer
• Halley E Gilbert,
  Chief Admin Officer & SVP
• Bryan E Roberts,
  Director
• Associatesvenrock Associate...,
  
• Management Llc Vr,
  10% owner
• Llc Fmr,
  10% owner
• Llcfil Ltd Fmr,
  
• Co Investment Holdings, Llc...,
  
• Capital Investments L.P.Rid...,
  
• Joseph C Jr Cook,
  Director
• George H Conrades,
  Director
• David Evans Shaw,
  Director
• David A Ebersman,
  Director
• Michael J Higgins,
  Chief Operating Officer
• Kelly Mac Donald,
  Chief Accounting Officer
• Jay Shepard,
  
• Sravan Kumar Emany,
  SVP, Chief Financial Officer
• Alexander J Sarissa Capital...,
  
• Andrew Davis,
  SVP, Chief Business Officer
• Ronald Silver,
  Principal Accounting Officer
• Minardo John,
  Chief Legal Officer